1.Ma, A, Malynn, BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nature Reviews Immunology 2012; 12(11): 774–785.
2.Bosanac, I, et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Molecular Cell 2010; 40(4): 548–557.
3.Tokunaga, F, et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO Journal 2012; 31(19): 3856–3870.
4.Verhelst, K, et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO Journal 2012; 31(19): 3845–3855.
5.Lee, EG, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289(5488): 2350–2354.
6.Boone, DL, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nature Immunology 2004; 5(10): 1052–1060.
7.Hitotsumatsu, O, et al. The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008; 28(3): 381–390.
8.Heyninck, K, Beyaert, R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Letters 1999; 442(2–3): 147–150.
9.Lu, TT, et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013; 38(5): 896–905.
10.Matmati, M, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nature Genetics 2011; 43(9): 908–912.
11.Hammer, GE, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nature Immunology 2011; 12(12): 1184–1193.
12.Vereecke, L, et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. Journal of Experimental Medicine 2010; 207(7): 1513–1523.
13.Kool, M, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011; 35(1): 82–96.
14.Lippens, S, et al. Keratinocyte-specific ablation of the NF-kappaB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death and Differentiation 2011; 18(12): 1845–1853.
15.Shao, L, et al. A20 restricts WNT signaling in intestinal epithelial cells and suppresses colon carcinogenesis. PLoS One 2013; 8(5): e62223.
16.Plenge, RM, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nature Genetics 2007; 39(12): 1477–1482.
17.Thomson, W, et al. Rheumatoid arthritis association at 6q23. Nature Genetics 2007; 39(12): 1431–1433.
18.Trynka, G, et al. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut 2009; 58(8): 1078–1083.
19.Zhernakova, A, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genetics 2011; 7(2): e1002004.
20.Dubois, PC, et al. Multiple common variants for celiac disease influencing immune gene expression. Nature Genetics 2010; 42(4): 295–302.
21.Majumdar, I, Ahuja, V, Paul, J. Altered expression of Tumor Necrosis Factor Alpha-Induced Protein 3 correlates with disease severity in Ulcerative Colitis. Scientific Reports 2017; 7(1): 9420.
22.Wang, K, et al. Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Human Molecular Genetics 2010; 19(10): 2059–2067.
23.Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447(7145): 661–678.
24.Adrianto, I, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nature Genetics 2011; 43(3): 253–258.
25.Graham, RR, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nature Genetics 2008; 40(9): 1059–1061.
26.Kim, SK, et al. TNFAIP3 gene polymorphisms associated with differential susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Korean population. Rheumatology (Oxford) 2014; 53(6): 1009–1013.
27.Dieude, P, et al. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population. Annals of the Rheumatic Diseases 2010; 69(11): 1958–1964.
28.Musone, SL, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes and Immunity 2011; 12(3): 176–182.
29.Nair, RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nature Genetics 2009; 41(2): 199–204.
30.Li, H, et al. TNFAIP3 gene polymorphisms confer risk for Behcet’s disease in a Chinese Han population. Human Genetics 2013; 132(3): 293–300.
31.Lodolce, JP, et al. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. The Journal of Immunology 2010; 184(12): 7001–7009.
32.Wang, X, et al. Alternative expression pattern of MALT1-A20-NF-kappaB in patients with rheumatoid arthritis. The Journal of Immunology Research 2014; 2014: 492872.
33.Zhou, Q, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics 2016; 48(1): 67–73.
34.Zhu, L, et al. Characteristics of A20 gene polymorphisms and clinical significance in patients with rheumatoid arthritis. Journal of Translational Medicine 2015; 13: 215.
35.Nakamura, BN, et al. A20 regulates canonical WNT-signaling through an interaction with RIPK4. PLoS One 2018; 13(5): e0195893.
36.Sherry, ST, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Research 2001; 29(1): 308–311.
37.Auton, A, et al. A global reference for human genetic variation. Nature 2015; 526(7571): 68–74.
38.Liu, JZ, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics 2015; 47(9): 979–986.
39.Zhang, L, et al. Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis risk: a meta-analysis. Archives of Medical Research 2017; 48(4): 386–392.
40.Rosenberg, NA, et al. Genome-wide association studies in diverse populations. Nature Reviews Genetics 2010; 11(5): 356–366.
41.Need, AC, Goldstein, DB. Next generation disparities in human genomics: concerns and remedies. Trends in Genetics 2009; 25(11): 489–494.
42.Afzali, A, Cross, RK. Racial and ethnic minorities with inflammatory bowel disease in the United States: a systematic review of disease characteristics and differences. Inflammatory Bowel Diseases 2016; 22(8): 2023–2040.
43.Hugot, JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411(6837): 599–603.
44.Danila, MI, et al. Dense genotyping of immune-related regions identifies loci for rheumatoid arthritis risk and damage in African Americans. Molecular Medicine 2017; 23: 177–187.
45.Ogura, Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411(6837): 603–606.
46.Inoue, N, et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology 2002; 123(1): 86–91.
47.Leong, RW, et al. NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. Alimentary Pharmacology & Therapeutics 2003; 17(12): 1465–1470.
48.Stahl, EA, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics 2010; 42(6): 508–514.
49.Zhang, MY, et al. Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus risk: an updated meta-analysis. HLA 2016; 88(5): 245–252.
50.Damas, OM, et al. Genetic characterization and influence on inflammatory bowel disease expression in a diverse Hispanic South Florida Cohort. Clinical and Translational Gastroenterology 2017; 8(4): e87.